Tocilizumab Discount Agreements (Biologika)
Original notice title
Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-27 - Tocilizumab
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
30 / 100
Risk factors
The procedure is explicitly not a public procurement under EU directives; legal recourse is via social courts, not proc...
No guaranteed volume or exclusivity; expected volumes might be lower than in exclusive contracts.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- Supplies contract
- 1 lot
- Duration until Oct 2026
- Conclusion of discount agreements for Tocilizumab
- Supply of Tocilizumab to insured persons
Show full summary
Open-House procedure for concluding discount agreements (Rabattverträge) for the active substance Tocilizumab with all eligible pharmaceutical entrepreneurs, as per § 130a Abs. 8 SGB V. The contract period is 12 months starting 01.11.2025, ending 31.10.2026. The lead buyer is Techniker Krankenkasse, with participating health insurance funds HEK, hkk, and KKH.
Risks
The procedure is explicitly not a public procurement under EU directives; legal recourse is via social courts, not proc...
No guaranteed volume or exclusivity; expected volumes might be lower than in exclusive contracts.
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical entrepreneur as defined in § 4 Abs. 18 AMG for the offered medicinal product
- Must have a valid marketing authorization for Tocilizumab according to § 21 Abs. 1 Satz 1 AMG
Eligibility
- Must submit a self-declaration (Anlage 4) confirming eligibility and reliability
Requirements may be incomplete.
Buyer
Location
Hamburg, DEU
Website
Identifier
992-80116-93
Activity
Health
Lots (1)
LOT-0001
Tocilizumab Discount Agreements (Biologika)
Conclusion of pharmaceutical discount agreements for Tocilizumab via open-house procedure.
Location
Duration
Category
Deadline
Award details
Ziel ist der Abschluss von Arzneimittelrabattverträgen nach § 130a Abs. 8 SGB V zu dem Wirkstoff Tocilizumab im Rahmen eines Open-House-Verfahrens.
Value note
Show original TED data
Original lot title
Open-House-Biologika-Rabattverträge 2025-27 - Tocilizumab
Original TED description
Ziel ist der Abschluss von Arzneimittelrabattverträgen nach § 130a Abs. 8 SGB V zu dem Wirkstoff Tocilizumab im Rahmen eines Open-House-Verfahrens.
Procurement Details
- Publication date
- 14 Sep 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 601421-2025
Documents (1)
Similar tenders
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Belgium – Pharmaceutical products – Antimycotica
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
France – Pharmaceutical products – 26-10 : ACCORD-CADRE DE FOURNITURE DE MÉDICAMENTS 2026
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
30 / 100
Risk factors
The procedure is explicitly not a public procurement under EU directives; legal recourse is via social courts, not proc...
No guaranteed volume or exclusivity; expected volumes might be lower than in exclusive contracts.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications